BioPharmSignal logoBioPharmSignal

Biotech News

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Nuvectis Pharma (NVCT)Nuvectis PharmaCompany update

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive...

Related news

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

IMTXImmatics2026-07-17 14:25 EST

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

View all latest news

Nuvectis Pharma

Nuvectis Pharma is an oncology company focused on targeted therapies for difficult cancers. Its development story is centered on precision oncology and smaller, data-sensitive programs.

Recent company news

NVCTNuvectis Pharma2025-09-04 07:30 EST

Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

NVCTNuvectis Pharma2025-08-11 16:30 EST

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

NVCTNuvectis Pharma2025-08-05 07:30 EST

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

NVCTNuvectis Pharma2025-07-31 07:45 EST

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

NVCTNuvectis Pharma2025-07-08 08:00 EST

Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

Stock data

Close
23.56 USD
Market cap
252.26M USD
Exchange
NYSE
Sector
Biopharma
Location
United States